At a Glance
- Investor: Blackstone Life Sciences
- Company: Anagram Therapeutics
- Deal value: $250 million
- Lead asset: ANG003
- Focus area: Exocrine pancreatic insufficiency (EPI)
What happened?
Blackstone Life Sciences said it is investing $250 million in Anagram Therapeutics to help fund the further development, approval and launch of ANG003, an orally delivered recombinant enzyme replacement therapy. Anagram is developing ANG003 for people with exocrine pancreatic insufficiency related to cystic fibrosis, pancreatic cancer and other disorders.
Why does it matter?
People with EPI often have to take a large number of pancreatic enzyme pills each day, and in cystic fibrosis that can mean as many as 40 pills daily. Anagram says ANG003 could reduce that burden substantially and may also become the first non-porcine extract product in the category, which would be a meaningful shift for patients and prescribers.
Who’s behind it?
Anagram is a clinical-stage biotech focused on oral enzyme therapeutics for malabsorption syndromes and nutrient metabolism disorders. Blackstone Life Sciences says the investment fits its model of using large-scale capital and operational support to back late-stage, clinically de-risked assets with clear patient need.
How was it achieved?
The investment follows positive clinical data for ANG003 in exocrine pancreatic insufficiency due to cystic fibrosis, plus more than $30 million in prior support from the Cystic Fibrosis Foundation. Blackstone is backing development through approval and launch, rather than just early discovery work, which is consistent with its broader life sciences strategy.
What’s next?
Anagram will use the capital to continue development and prepare ANG003 for regulatory review and eventual launch. If successful, the therapy could reach patients with CF, pancreatic cancer and other EPI-related conditions, while potentially reducing pill burden and simplifying treatment.
What are people saying?
Blackstone Life Sciences head Nicholas Galakatos said the company sees Anagram as well positioned to transform treatment for pancreatic insufficiency, especially in cystic fibrosis. He also described the investment as a case study in Blackstone’s “ownership strategy” of pairing capital with hands-on engagement.